Boston Scientific (BSX) EBIT Margin (2009 - 2026)

Boston Scientific has disclosed EBIT Margin across 18 years of filings, most recently posting 21.16% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 21.16%, up 141.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 18.4% (up 217.0% YoY), and the FY2025 annual result was 18.0%, up 246.0% from the prior year.
• EBIT Margin came in at 21.16% for Q1 2026 at Boston Scientific, up from 15.61% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 21.16% in Q1 2026 to a low of 11.29% in Q3 2022.
• The 5-year median for EBIT Margin is 15.68% (2023), against an average of 16.1%.
• Across the five-year window, EBIT Margin surged 836 bps in 2023 and slumped 223 bps in 2024, its largest moves.
• Boston Scientific's EBIT Margin stood at 12.4% in 2022, then grew by 26 bps to 15.68% in 2023, then dropped by 6 bps to 14.8% in 2024, then advanced by 5 bps to 15.61% in 2025, then surged by 36 bps to 21.16% in 2026.
• The last three EBIT Margin figures came in at 21.16% (Q1 2026), 15.61% (Q4 2025), and 20.69% (Q3 2025), per Business Quant data.